John Overdeck’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.4M | Buy |
724,604
+197,753
| +38% | +$4.67M | 0.01% | 1117 |
|
|
2026
Q1 | $11.9M | Buy |
526,851
+74,999
| +17% | +$1.67M | 0.01% | 1285 |
|
|
2025
Q4 | $11.7M | Buy |
451,852
+218,858
| +94% | +$5.2M | 0.02% | 1016 |
|
|
2025
Q3 | $6M | Buy |
232,994
+126,152
| +118% | +$3.1M | 0.01% | 1313 |
|
|
2025
Q2 | $2.55M | Sell |
106,842
-11,502
| -10% | -$290K | ﹤0.01% | 1660 |
|
|
2025
Q1 | $2.94M | Buy |
118,344
+3,662
| +3% | +$87.7K | 0.01% | 1477 |
|
|
2024
Q4 | $2.16M | Buy |
114,682
+45,222
| +65% | +$794K | ﹤0.01% | 1659 |
|
|
2024
Q3 | $1.05M | Sell |
69,460
-6,563
| -9% | -$112K | ﹤0.01% | 2094 |
|
|
2024
Q2 | $2.18M | Sell |
76,023
-33,717
| -31% | -$960K | 0.01% | 1500 |
|
|
2024
Q1 | $3.21M | Buy |
109,740
+73,829
| +206% | +$2.27M | 0.01% | 1200 |
|
|
2023
Q4 | $1.21M | Sell |
35,911
-61,036
| -63% | -$1.79M | ﹤0.01% | 1963 |
|
|
2023
Q3 | $2.97M | Sell |
96,947
-46,275
| -32% | -$1.67M | 0.01% | 1157 |
|
|
2023
Q2 | $5.74M | Buy |
143,222
+117,938
| +466% | +$4.88M | 0.01% | 863 |
|
|
2023
Q1 | $1.03M | Buy |
+25,284
| New | +$1.01M | ﹤0.01% | 1852 |
|
|
2022
Q2 | – | Sell |
-17,594
| Closed | -$1.34M | – | 2837 |
|
|
2022
Q1 | $1.34M | Sell |
17,594
-49,886
| -74% | -$3.33M | ﹤0.01% | 1551 |
|
|
2021
Q4 | $4.06M | Sell |
67,480
-42,398
| -39% | -$2.34M | 0.01% | 1319 |
|
|
2021
Q3 | $6.15M | Sell |
109,878
-256,353
| -70% | -$14.8M | 0.01% | 1085 |
|
|
2021
Q2 | $22.2M | Buy |
366,231
+277,883
| +315% | +$17.6M | 0.05% | 452 |
|
|
2021
Q1 | $6.19M | Buy |
88,348
+5,177
| +6% | +$370K | 0.02% | 934 |
|
|
2020
Q4 | $4.98M | Sell |
83,171
-63,642
| -43% | -$3.73M | 0.01% | 939 |
|
|
2020
Q3 | $8.83M | Buy |
+146,813
| New | +$8.53M | 0.03% | 551 |
|
|
2020
Q2 | – | Sell |
-39,675
| Closed | -$1.33M | – | 3388 |
|
|
2020
Q1 | $1.33M | Sell |
39,675
-92,199
| -70% | -$3.83M | 0.01% | 1220 |
|
|
2019
Q4 | $5.97M | Buy |
+131,874
| New | +$5.6M | 0.02% | 860 |
|
|
2019
Q3 | – | Sell |
-273,743
| Closed | -$11.9M | – | 3721 |
|
|
2019
Q2 | $11.9M | Buy |
273,743
+75,818
| +38% | +$3.22M | 0.04% | 521 |
|
|
2019
Q1 | $7.53M | Sell |
197,925
-88,503
| -31% | -$3.45M | 0.02% | 781 |
|
|
2018
Q4 | $12.3M | Buy |
286,428
+112,559
| +65% | +$5.25M | 0.05% | 482 |
|
|
2018
Q3 | $8.55M | Buy |
+173,869
| New | +$7.52M | 0.02% | 705 |
|
|
2018
Q1 | – | Sell |
-162,121
| Closed | -$7.4M | – | 3419 |
|
|
2017
Q4 | $7.4M | Buy |
162,121
+107,321
| +196% | +$4.25M | 0.02% | 719 |
|
|
2017
Q3 | $2.06M | Sell |
54,800
-217,016
| -80% | -$8.73M | 0.01% | 1291 |
|
|
2017
Q2 | $13M | Buy |
271,816
+32,342
| +14% | +$1.5M | 0.05% | 435 |
|
|
2017
Q1 | $10.9M | Buy |
239,474
+558
| +0.2% | +$24.1K | 0.04% | 586 |
|
|
2016
Q4 | $7.72M | Buy |
238,916
+59,777
| +33% | +$1.99M | 0.03% | 635 |
|
|
2016
Q3 | $6.13M | Sell |
179,139
-30,655
| -15% | -$1.2M | 0.02% | 778 |
|
|
2016
Q2 | $7.08M | Buy |
209,794
+145,780
| +228% | +$7.16M | 0.03% | 619 |
|
|
2016
Q1 | $3.39M | Buy |
64,014
+52,853
| +474% | +$3.09M | 0.02% | 890 |
|
|
2015
Q4 | $857K | Sell |
11,161
-5,855
| -34% | -$332K | ﹤0.01% | 1614 |
|
|
2015
Q3 | $699K | Buy |
+17,016
| New | +$1.04M | ﹤0.01% | 1385 |
|
|
2014
Q4 | – | Sell |
-228,775
| Closed | -$22.2M | – | 2344 |
|
|
2014
Q3 | $22.2M | Buy |
228,775
+150,059
| +191% | +$14.6M | 0.1% | 268 |
|
|
2014
Q2 | $7.23M | Buy |
78,716
+26,009
| +49% | +$1.98M | 0.03% | 592 |
|
|
2014
Q1 | $3.69M | Buy |
+52,707
| New | +$3.58M | 0.02% | 735 |
|
Other funds holding PCRX
DPCM
John Overdeck's PCRX Position: Q2 2026 in Review
John Overdeck increased its Pacira BioSciences (PCRX) stake by 38% in Q2 2026, buying an estimated $4.67M and bringing the position to 724,604 shares worth $18.4M. The position accounts for 0.01% of the portfolio, ranked #1117.
John Overdeck first reported a position in PCRX in Q1 2014 and has held it in 40 quarters since. The position peaked at $22.2M in Q2 2021. 251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- John Overdeck held 724,604 shares of Pacira BioSciences worth $18.4M as of Q2 2026.
- John Overdeck bought 197,753 Pacira BioSciences shares in Q2 2026, an estimated $4.67M.
- Pacira BioSciences made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1117 holding.
- John Overdeck first reported a position in Pacira BioSciences in Q1 2014 and has held it in 40 quarters since.
- John Overdeck's Pacira BioSciences position peaked at $22.2M in Q2 2021.
- 251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.